文献速递胸部肿瘤

已发表基因表达预后特征的综合评估:用于基于生物标志物的肺癌临床研究

Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies.
PubMed 文献 · Ann Oncol · 2017-01-01

本研究对已发表的切除非小细胞肺癌(NSCLC)mRNA预后特征进行系统综述与Meta分析,纳入15项研究共1927例早期患者,用风险比、一致性评分和时间依赖ROC评估各特征预后效能,并对比100个随机特征。共识别42个特征,25个在校正临床风险因素后仍具预后价值,18个显著优于随机特征;腺癌和鳞癌分别有17个和8个特征具预后价值。表现最佳的特征在预测患者结局上高度一致。

要点

  • 系统综述与Meta分析纳入15项研究共1927例早期NSCLC患者。
  • 42个已发表预后特征中,25个在校正临床风险因素后仍与生存相关。
  • 18个特征显著优于随机特征,腺癌和鳞癌分别有17个和8个特征具预后价值。

核心结论

  • 基于大规模Meta分析,识别出一组适合在前瞻性临床研究中进一步验证的mRNA表达预后特征。

研究设计与样本

  • 对已发表的切除NSCLC mRNA预后特征进行系统综述与Meta分析,纳入15项研究共1927例早期NSCLC患者,使用风险比、一致性评分和时间依赖ROC三种指标评估预后效能,并与100个随机特征对比,采用多因素Cox模型评估独立于临床风险因素的预后能力。

主要发现

  • 共识别42个源自全基因组表达谱分析的肺癌预后特征。
  • 校正临床风险因素后,25个特征对生存具预后价值。
  • 18个特征显著优于随机特征。
  • 分别分析组织学类型时,17个特征对腺癌具预后价值,8个特征对鳞状细胞肺癌具预后价值。
  • 已发表基因特征间重叠少,但表现最佳的特征在预测患者结局上高度一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A more accurate prognosis for non-small-cell lung cancer (NSCLC) patients could aid in the identification of patients at high risk for recurrence. Many NSCLC mRNA expression signatures claiming to be prognostic have been reported in the literature. The goal of this study was to identify the most promising mRNA prognostic signatures in NSCLC for further prospective clinical validation. EXPERIMENTAL DESIGN: We carried out a systematic review and meta-analysis of published mRNA prognostic signatures for resected NSCLC. The prognostic performance of each signature was evaluated via a meta-analysis of 1927 early stage NSCLC patients collected from 15 studies using three evaluation metrics (hazard ratios, concordance scores, and time-dependent receiver-operating characteristic curves). The performance of each signature was then evaluated against 100 random signatures. The prognostic power independent of clinical risk factors was assessed by multivariate Cox models. RESULTS: Through a literature search, we identified 42 lung cancer prognostic signatures derived from genome-wide expression profiling analysis. Based on meta-analysis, 25 signatures were prognostic for survival after adjusting for clinical risk factors and 18 signatures carried out significantly better than random signatures. When analyzing histology types separately, 17 signatures and 8 signatures are prognostic for adenocarcinoma and squamous cell lung cancer, respectively. Despite little overlap among published gene signatures, the top-performing signatures are highly concordant in predicted patient outcomes. CONCLUSIONS: Based on this large-scale meta-analysis, we identified a set of mRNA expression prognostic signatures appropriate for further validation in prospective clinical studies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Tang H, Wang S, Xiao G, et al. Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies. Ann Oncol. 2017. PMID: 28200038. doi:10.1093/annonc/mdw683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。